Académique Documents
Professionnel Documents
Culture Documents
doi: 10.3122/jabfm.2014.01.130145
151
Vol. 27 No. 1
http://www.jabfm.org
US Trade
Name
Elavil
Wellbutrin
Class*
TCA
NDRI
Dosage Forms
Usual
Frequency
Tablet
Tablet
Once a day
Three times
daily
Wellbutrin SR
Twice a day
Wellbutrin XL
Once a day
Citalopram
Celexa
SSRI
Tablet, solution Once a day
Desvenlafaxine Pristiq
SNRI Tablet
Once a day
Duloxetine
Cymbalta
SNRI Capsule
Once a day
Escitalopram
Lexapro
SSRI
Tablet, solution Once a day
Fluoxetine
Prozac
SSRI
Tablet, capsule, Once a day
solution
Prozac Weekly
Capsule
Once a
week
Fluvoxamine Luvox
SSRI
Tablet
Twice a day
Luvox CR
Capsule
Once a day
Milnacipran
Savella
SNRI Tablet
Twice a day
Mirtazapine
Remeron
NaSSA Tablet
Once a day
Remeron
Oral
SolTab
disintegrating
tablet
Nefazodone** Serzone
SARI
Tablet
Twice a day
Nortriptyline Pamelor
TCA
Capsule,
Once a day
solution
Paroxetine
Paxil
SSRI
Tablet, solution Once a day
Paxil CR
Tablet
Sertraline
Zoloft
SSRI
Tablet, solution Once a day
Trazodone
Desyrel
SARI
Tablet
Three times
daily
Oleptro
Once a day
Venlafaxine
Effexor
SNRI Tablet
Twice a day
Venlafaxine
Once a day
ER
Effexor XR
Capsule
Once a day
Vilazodone
Viibryd
SPARI Tablet
Once a day
C
C
C
C
C
NR
NR
Yes
Yes
Yes
No
$
$$
R:B
NR
NR
R:B
NR
Yes
Yes
Yes
No
No
Yes
Yes
No
No
Yes
No
No
No
Yes
$$
$$$
$
$$$$
$$$$
$$$
$
Yes
No
$$$
Yes
No
No
Yes
Yes
No
No
No
No
No
$$$
$$$$
$$$
$
$$
R:B
C
C
NR
R:B
C
D
NR
NR
Yes
Yes
No
Yes
$$
$
Safe
C
C
Safe
R:B
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
$
$$$
$
$
NR
No
Yes
Yes
No
No
No
$$$
$$
$$$
No
No
$$$$
NR
No
No
$$$$
*TCA, tricyclic antidepressant; NDRI, norepinephrine dopamine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor;
SNRI, serotonin norepinephrine reuptake inhibitor; NaSSA, noradrenergic specic serotonergic antidepressant; SARI, serotonin
antagonist reuptake inhibitor; SPARI, serotonin partial agonist reuptake inhibitor.
C, no adequate or well-controlled studies in humans; D, positive evidence of human fetal risk based on adverse reaction data or
studies in humans.
NR, not recommended; R:B, weigh risk-benet; safe, safe for nursing; based on Lexicomp Online Clinical Databases (http://
online.lexi.com).
Available for a low monthly cost through programs offered by large chain stores (e.g., Walmart, Kroger, Sams Club, Target, Costco,
CVS, Kmart, Walgreens).68
$ $50 per month; $$ $50 to $100 per month; $$$ $100 to $150 per month; $$$$ $150 per month; based on 2011
Consumer Reports Health Best Buy Drugs.68
In the United States, uvoxamine is approved only for obsessive-compulsive disorder; milnacipran is approved only for bromyalgia;
both agents are used off-label to treat depression.19,24
**Serzone, the brand name form of nefazodone, was discontinued in 2004 because of hepatotoxicity; generic nefazodone is available
with a black box warning for liver failure.57
Approved in 2011, vilazodone is the newest antidepressant in a novel therapeutic class; given that data is limited, it is not discussed
in this article.
doi: 10.3122/jabfm.2014.01.130145
153
Vol. 27 No. 1
Recommended Classes
First-line
Classes
to Avoid Antidepressants
SSRI
NDRI
SNRI
Citalopram
Escitalopram
Fluvoxamine
Sertraline
NDRI, norepinephrine dopamine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor.
http://www.jabfm.org
Recommended
Classes
Classes
to Avoid
First-line
Antidepressants
Fatigue
Anhedonia
Weight gain
NDRI
SNRI
Activating SSRI
NaSSA
SARI
Bupropion
Desvenlafaxine
Fluoxetine
Venlafaxine
doi: 10.3122/jabfm.2014.01.130145
Recommended
Classes
Classes
to Avoid
First-line
Antidepressants
Insomnia
Hyperarousal
Weight loss
NaSSA
SARI
Sedating SSRI
NDRI
SNRI
Mirtazapine
Nefazodone
Paroxetine
Trazodone
155
Recommended
Classes
Classes
to Avoid
First-line
Antidepressants
TCA
SNRI
None
Amitriptyline
Duloxetine
Milnacipran
Nortriptyline
a SNRI that is FDA approved to treat major depression as well as painful diabetic peripheral neuropathy, bromyalgia, and chronic musculoskeletal
pain.23 Milnacipran is an SNRI that is approved in
the United States only for the treatment of bromyalgia, but it is popular in other countries for
treatment of depression.24 There are only a few
studies that directly compare an SNRI with other
antidepressants for treating depression with pain,
and all these studies are awed and underpowered.53 It is hoped that future research will elucidate the exact role of SNRIs in the treatment of
painful depression. What has been used for decades
as effective treatment for a number of chronic pain
conditionsincluding idiopathic neuropathy,58 bromyalgia,59 painful diabetic neuropathy,60 prophylaxis of episodic migraine,61 and chronic musculoskeletal pain62are TCAs such as amitriptyline and
nortriptyline. Although TCAs are older and in general less well-tolerated than newer antidepressants,
they have a similar if not better efcacy in treating
depression.63 TCAs also have the added advantage of
50 years of experience in the hands of psychiatrists
and primary care doctors.63 Therefore, under the
current proposal, the best antidepressants to treat
depression with chronic pain are duloxetine, milnacipran, amitriptyline, and nortriptyline (Table 5).
An individualized, patient-centered treatment
model for depression, created around a targeted
symptom cluster-based approach to antidepressant
selection, is described herein (Tables 2 to 5). In
healthy adults with unipolar major depressive disorder, the choice of antidepressants should be
guided primarily by the patients dominant symptom cluster. Patients do not need to have all the
symptoms in a symptom cluster to warrant treatment. Further distinction between medications in
the same cluster may be guided by comorbid medical or psychiatric conditions, previous response (or
Vol. 27 No. 1
Conclusion
Unipolar major depressive disorder is a common,
disabling, and costly disease that is the leading
http://www.jabfm.org
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
References
1. Kessler RC, Berglund P, Demler O, et al. Lifetime
prevalence and age-of-onset distributions of DSM-IV
disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593 602.
2. Kessler RC, Berglund P, Demler O, et la; National
Comorbidity Survey Replication. The epidemiology
of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
JAMA 2003;289:3095105.
3. Wang PS, Lane M, Olfson M, Pincus HA, Wells
KB, Kessler RC. Twelve-month use of mental health
services in the United States: results from the National Comorbidity Survey Replication. Arch Gen
Psychiatry 2005;62:629 40.
4. Agency for Health Care Policy and Research. Depression Guideline Panel, Vol 2: treatment of major
depression, clinical practice guideline, no 5. Rockville, MD: Agency for Health Care Policy and Re-
doi: 10.3122/jabfm.2014.01.130145
15.
16.
17.
18.
19.
157
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
Vol. 27 No. 1
http://www.jabfm.org
doi: 10.3122/jabfm.2014.01.130145
159